Compare Adaptive Biotechnologies Corp (ADPT) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Fortinet Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.94 (market cap $4.04B), while Fortinet Inc trades at $161.15 (market cap $118.78B). The key difference: Fortinet Inc is far larger — about 29.4× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | FTNT | |
|---|---|---|
Market Cap | $4.04B | $118.78B |
Sector | Health | Technology |
52-Week High | $25.45 | $168.29 |
52-Week Low | $12.30 | $75.23 |
Enterprise Value | $4.10B | $115.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Fortinet (FTNT) trades at $161.21, down 1.83% over 24 hours, with a bullish technical signal from moving averages and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $0.90 versus $0.746 expected, driven by robust demand for cybersecurity solutions amid AI-driven security needs. Revenue growth has accelerated from $4.4B in 2022 to $6.8B in 2025, with net income margins above 28%, though valuation ratios like P/E of 57.2 indicate premium pricing.
The outlook remains positive given consistent earnings beats and analyst consensus price target of $174.50, offering ~8% upside. Key risks include high valuation multiples, competitive pressures in cybersecurity, and negative net cash flow trends. Institutional sentiment is mixed with 42.65% buy ratings, but growth in AI security and SASE firewall adoption supports long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
